Electrochemical immunoplatform to help managing pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is the solid tumor with worst prognosis, representing today third cause of cancer-related deaths in developed countries and expected to be second 2030. Today, CA19-9 remains only clinically used marker for management PDAC (FDA-approved as a disease monitoring marker). This work reports disposable amperometric immunoplatform determination CA19-9. The skilfully combines advantages magnetic microsupports (MBs) implementation immunoassay transduction on screen-printed carbon electrodes (SPCEs). method involves preparation sandwich immunocomplexes enzymatically labeled enzyme horseradish peroxidase (HRP) MBs uses detection antibody conjugated HRP. Once HRP-labeled immunocomplexes-bearing were trapped SPCE surface, variation cathodic current was measured presence H2O2 hydroquinone (HQ), which directly proportional concentration Under optimized experimental conditions, allowed standards over 5.0 500 U mL−1 range, limit (LOD) value 1.5 1 h. exhibits good reproducibility selectivity immunoconjugates shows storage stability. applied serum samples medium-sized cohort (22 individuals) healthy subjects patients diagnosed PDAC. obtained results demonstrated ability discriminate both types individuals within h after sample dilution. represents an improvement terms cost, applicability accessibility compared ELISA-based techniques currently clinic.